Objectif Peripheral Nerve Injuries (PNIs) are lesions of the nerves of the head or the extremities. Grand View Research estimates over 2 million cases of PNIs per year in the EU and the USA. These injuries remain incurable, resulting in permanent loss of body function as in paraplegia, leading to disabilities and heavy social burden. The chance to cure PNIs based on smart nano-engineered biomaterials will have a major positive impact in heavy and long term burdens on patients and healthcare systems. In this context, Nerve Biomed’s team, a spin-off company of the Polytechnic University of Valencia (Spain) has been leading an R&D initiative in advanced PNI reparation over the past 11 years, in order to develop and further commercialise ULTRANERVE: an easy-to-use medical solution for PNI regeneration, which is going to simplify medical procedures and reduce the average full recovery time, while decreasing significantly the average cost of actual repair procedures.Within the roadmap established by the company to commercialize the product internationally by 2020, Nerve Biomed wants to perform a thorough feasibility study, through this SME Instrument Phase 1, which will assess in detail the practical and economic viability of introducing this solution in the PNI repair and regeneration market ih the EU and the USA. Champ scientifique medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsmedical and health sciencesclinical medicinephysiotherapymedical and health sciencesmedical biotechnologynanomedicinemedical and health sciencesclinical medicineoncologymedical and health sciencesbasic medicineneurology Programme(s) H2020-EU.2.1.2. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies Main Programme H2020-EU.2.1.5. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing H2020-EU.2.1.3. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument Thème(s) SMEInst-02-2016-2017 - Accelerating the uptake of nanotechnologies advanced materials or advanced manufacturing and processing technologies by SMEs Appel à propositions H2020-SMEInst-2016-2017 Voir d’autres projets de cet appel Sous appel H2020-SMEINST-1-2016-2017 Régime de financement SME-1 - SME instrument phase 1 Coordinateur NERVE BIOMED SOCIEDAD LIMITADA Contribution nette de l'UE € 50 000,00 Adresse CALLE CANONIGO MOLINA ALONSO, NUM. 6 04004 ALMERIA Espagne Voir sur la carte PME L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention. Oui Région Sur Andalucía Almería Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Liens Contacter l’organisation Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 71 429,00